Mark T. Fleming, MD | Authors


SPOTLIGHT Shines on Inadequacy of Standard Imaging in Prostate Cancer

June 24, 2022

Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.